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Abstract
Purpose Insulin resistance, dyslipidemia and increased systemic inflammation are important risk factors for chronic kidney 
disease (CKD). Hence, vitamin D administration might be an appropriate approach to decrease the complications of CKD. 
Randomized controlled trials assessing the effects of vitamin D supplementation or treatment on glycemic control, lipid 
profiles, and C-reactive protein (CRP) among patients with CKD were included.
Methods Two independent authors systematically searched online databases including EMBASE, Scopus, PubMed, Cochrane 
Library, and Web of Science in November 2018 with no time restriction. Cochrane Collaboration risk of bias tool was applied 
to assess the methodological quality of included trials. Between-study heterogeneity was estimated using the Cochran’s Q 
test and I-square (I2) statistic. Data were pooled using a random-effects model and weighted mean difference (WMD) was 
considered as the overall effect size.
Results Of the 1358 citations identified from searches, 17 full-text articles were reviewed. Pooling findings from five stud-
ies revealed a significant reduction in fasting glucose (WMD: − 18.87; 95% CI: − 23.16, − 14.58) and in homeostatic model 
assessment of insulin resistance (HOMA-IR) through three studies (WMD: − 2.30; 95% CI: − 2.88, − 1.72) following the 
administration of vitamin D. In addition, pooled analysis revealed a significant reduction in triglycerides (WMD: − 32.52; 
95% CI: − 57.57, − 7.47) through six studies and in cholesterol concentrations (WMD: − 7.93; 95% CI: − 13.03, − 2.83) 
through five studies, following vitamin D supplementation or treatment, while there was no effect on insulin, HbA1c, LDL 
and HDL cholesterol, and CRP levels.
Conclusions This meta-analysis demonstrated the beneficial effects of vitamin D supplementation or treatment on improv-
ing fasting glucose, HOMA-IR, triglycerides and cholesterol levels among patients with CKD, though it did not influence 
insulin, HbA1c, LDL and HDL cholesterol, and CRP levels.
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Introduction
People with chronic kidney disease (CKD), including 
patients undergoing hemodialysis (HD), have a high inci-
dence of cardiovascular diseases (CVDs) due to enhanced 
atherosclerosis [15]. Although the physiopathology of 
atherosclerosis is not yet fully recognized, there is a close 
relationship between inflammation and atherosclerosis 
[50]. The inflammatory cascade can be initiated by meta-
bolic disorders and risk factors of atherosclerosis such as 
atherogenic dyslipidemia, insulin resistance and elevated 
blood glucose concentration [25]. Impaired glucose metab-
olism and increased insulin resistance are well-known 
complications at all stages of CKD [8, 12].
Vitamin D is a fat-soluble secosteroid that is well rec-
ognized due to its function in calcium metabolism and 
bone mineralization [24]. Prior investigations have demon-
strated that hypovitaminosis D is common in people with 
CKD [7, 8]. Reduced vitamin D levels are related with ele-
vated systemic inflammatory factors and insulin resistance 
in this condition [35]. Based on a previous meta-analysis, 
each 10 ng/ml decrement in vitamin D value elevates the 
all-cause mortality risk by 14% in people with CKD [36]. 
Another meta-analysis documented a 37% reduction in 
CVDs mortality with vitamin D supplementation in CKD 
patients [10]. Our recent meta-analyses also showed the 
favorable impacts of vitamin D intake on C-reactive pro-
tein (CRP) levels among patients with diabetes mellitus 
and polycystic ovarian syndrome [2, 26]. In a meta-analy-
sis of 17 randomized controlled trials (RCTs), Jafari et al. 
[18] revealed that vitamin D administration ameliorated 
total, LDL cholesterol, and triglyceride concentrations in 
patients with type 2 diabetes mellitus (T2DM). In another 
study, vitamin D supplementation significantly reduced 
insulin resistance in patients with T2DM [22]. However, 
administration of vitamin D did not affect glycemic con-
trol and lipid profiles in people with non-alcoholic fatty 
liver disease [39]. Some RCTs have evaluated the effect 
of vitamin D on glucose homeostasis, lipid profiles, and 
CRP in people with CKD [20, 21, 40, 46]. Therefore, the 
results of those clinical trials are inclusive, with studies 
that favored vitamin D effects, while other studies did not 
show any beneficial effects of this micronutrient. Using 
different dosages of vitamin D, as well as differences in 
study design and characteristics of participants are the 
probable reasons that may explain the conflicting results 
about glycemic control, lipid profile and CRP in patients 
CKD.
To the best of our knowledge, no earlier study has sys-
tematically reviewed findings from RCTs on the effect of 
vitamin D supplementation or treatment or metabolic sta-
tus in patients with CKD. Therefore, the present study was 
done to systematically summarize the present evidence of 
RCTs on the influence of vitamin D supplementation or 
treatment on glycemic control, lipid profiles, and CRP in 
these patients and to run a meta-analysis, if possible.
Methods
Search and study selection strategies
The scientific international databases, including Cochrane 
Library, EMBASE, PubMed, and Web of Science were 
searched for relevant studies published up to November 
2018 with no time restriction. A search strategy was devel-
oped using the following MeSH and text keywords: patients 
[“CKD” OR “HD” OR “chronic renal failure” OR “ESRD” 
OR “disorders related to kidney], AND intervention (“vita-
min D” OR “colecalciferol” OR “ergocalciferol” OR “calci-
triol” AND “supplementation” OR “intake” OR “administra-
tion” OR “treatment”), and outcomes (“fasting glucose” OR 
“fasting plasma glucose (FPG)” OR “insulin” OR “homeo-
stasis model assessment of insulin resistance (HOMA-IR)” 
OR “HbA1c” AND “total cholesterol (TC)” “triglycerides 
(TG)” OR “low-density lipoprotein (LDL cholesterol)” OR 
“LDL-C” OR “high-density lipoprotein (HDL cholesterol)” 
OR “HDL-C” OR “CRP”). We also checked the reference 
list of published reviews to avoid missing any potentially 
eligible studies. A professional librarian educated in research 
strategies help us to perform the literature review.
Inclusion and exclusion criteria
All CTs with either parallel or cross-over design that inves-
tigated the effect of any dosages of vitamin D supplementa-
tion or treatment on glycemic control and used placebo as 
the control group among patients with CKD were included. 
Furthermore, we included calcitriol due to fewer side effects. 
Animal experiments, in vitro studies, case reports, observa-
tional studies, studies that did not have control group, and 
those studies that did not achieve the least quality score were 
excluded. In addition, studies in which vitamin D analogs 
other than calcitriol were used as the intervention and those 
without placebo group were also excluded.
Data extraction and quality assessment
Two independent authors (SA and VO) screened retrieved 
articles for the eligibility. In the first step, the title and 
abstract of studies were reviewed. Then, the full text of 
relevant studies was retrieved and assessed to ascertain the 
suitability of a study for inclusion into the meta-analysis. 
Any disagreement was discussed and resolved by the third 
author (ZA).
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Following data were then extracted and entered into an 
Excel database: first authors name, year of publication, study 
location, age, study design, sample size, dosage of interven-
tion, duration of study, type of disease, the mean and stand-
ard deviation (SD) for fasting glucose, insulin, HOMA-IR, 
HbA1c, lipid profiles and CRP in each intervention group. 
The quality of studies included was assessed by the same 
independent authors using the Cochrane Collaboration risk 
of bias tool based on the following criteria: “randomization 
generation, allocation concealment, blinding of participants 
and outcome assessors, incomplete outcome data, and selec-
tive outcome reporting, and other sources of bias” [17].
Data synthesis and statistical analysis
We fitted fixed effects (FE) models and used forest plots to 
display the weighted mean differences (WMDs) with 95% CI 
for fasting plasma glucose, insulin, HOMA-IR, HbA1c, tri-
glycerides, total cholesterol, LDL cholesterol, HDL choles-
terol and CRP which were calculated from mean changes in 
these variables throughout the vitamin D supplementation or 
treatment comparing to placebo. If a study had no sufficient 
data, we tried to get them through contact with the authors.
Between-study heterogeneity across included studies 
was evaluated using Cochran’s Q test (with significant P 
value < 0.1) and I-square test. I2 greater than 50% was con-
sidered as significant heterogeneity [17]. If between-study 
heterogeneity was high, we used a random-effects model to 
calculate the pooled estimates. Baseline and final values of 
the mentioned outcomes for both intervention and placebo 
groups were extracted from the included studies to calculate 
mean changes with SD for each variable. In addition, we 
used a subgroup analysis to detect probable sources of het-
erogeneity using a FE model. Visual inspection of the funnel 
plot as well as Egger’s regression test was used to explore 
the publication bias. Both STATA 11.0 (Stata Corp., College 
Station, TX) and Review Manager 5.3 (Cochrane Collabora-
tion, Oxford, UK) were used for data analysis.
Results
Characteristics of included studies
Overall, 17 studies were included in this systematic review 
and meta-analysis. A PRISMA flow diagram was used to 
provide a detailed description of the review process includ-
ing the number of trials that were finally included (Fig. 1). 
Included studies were published from 1992 to 2018. They 
enrolled 1781 patients with CKD (888 intervention and 893 
control patients). Characteristics of the included studies are 
shown in Table 1. The mean age of patients was 60.78 years. 
Among them, 1395 patients (through 11 studies) were 
under HD. Five studies were done in Iran, three studies in 
Denmark, two studies in USA, and the others were done 
in Turkey, India, China, Brazil, Germany, Spain, and UK. 
Calcidiol, calcitriol, and ergocalciferol were used as differ-
ent types of vitamin D in the included studies. Supplements 
were used in daily, weekly, single, and double doses. The 
duration of intervention varied between 3 and 52 weeks. The 
measured outcomes in these studies were concentrations of 
fasting glucose, insulin, HOMA-IR, HbA1c, triglycerides, 
total, LDL, HDL cholesterol, and CRP.
Findings for the effect of vitamin D 
supplementation or treatment on glycemic control
Combining five studies, we found 18.87 mg/day reduction in 
fasting blood glucose following vitamin D supplementation 
or treatment compared with the placebo (WMD: − 18.87; 
95% CI: − 23.16, − 14.58) (Fig. 2a). Subgroup analysis by 
the participants’ age (< 50 years vs. ≥ 50 years) did not 
change the overall findings (Table 2). When we combined 
effect sizes from four studies on the effect of vitamin D sup-
plementation or treatment on serum insulin levels and from 
another set of four studies on HbA1C, no significant changes 
Articles screened by title and 
abstract (n=205)
Full text articles assessed for 
eligibility (n=25)
Studies included in this study 
(n=17)
Article excluded (n=1153) due to duplicate 
articles, not randomized controlled trials, 
review and not human 
Excluded non-relevant articles (n=180)
Articles excluded (n=8):
1. No relevant outcome reported (n=4)
2. Not control group (n=3)
3. Healthy control group (n=1)
Articles identified through 
electronic database search 
(n=1358)
EMBASE (n=267), Scopus 
(n=328), PubMed (n=416), 
Cochrane Library (n=141) and 
Web of Science (n=206)
Fig. 1  Literature search and review flowchart for selection of studies
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were seen [for insulin: (WMD: − 2.25; 95% CI: − 7.18, 
2.67), for HbA1C: (WMD: − 0.69; 95% CI: − 1.71, 0.33)] 
(Fig. 2b, c). Combining findings from three studies, vitamin 
D supplementation or treatment resulted in significant reduc-
tion in HOMA-IR (WMD: − 2.30; 95% CI: − 2.88, − 1.72) 
(Fig. 2d).
NOTE: Weights are from random effects analysis
Overall  (I-squared = 73.9%, p = 0.004)
Khajehdehi et al. (2003)
Study
Esfandiari et al. (2019)
ID
Tamadon et al. (2018)
Turk et al. (1992)
Bonakdaran et al. (2008)
-18.87 (-23.16, -14.58)
-19.35 (-21.73, -16.97)
-18.41 (-21.49, -15.33)
WMD (95% CI)
-20.60 (-33.40, -7.80)
-13.44 (-17.65, -9.23)
-49.26 (-69.09, -29.43)
100.00
31.57
%
29.63
Weight
8.50
26.16
4.13
0-69.1 69.1
NOTE: Weights are from random effects analysis
Overall  (I-squared = 94.8%, p = 0.000)
Bonakdaran et al. (2008)
Turk et al. (1992)
Esfandiari et al. (2019)
Study
Tamadon et al. (2018)
ID
-2.25 (-7.18, 2.67)
-5.57 (-10.07, -1.07)
3.24 (1.60, 4.88)
-1.78 (-4.51, 0.95)
-5.40 (-6.99, -3.81)
WMD (95% CI)
100.00
22.14
26.37
25.07
%
26.42
Weight
0-10.1 10.1
(a)
(b)
Fig. 2  Meta-analysis glycemic control weighted mean difference estimates for a fasting glucose, b insulin, c HOMA-IR, d HbA1c in the vitamin 
D supplements and control groups (CI = 95%)
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Findings for the effect of vitamin D 
supplementation or treatment on lipid profiles
Compared with the placebo, vitamin D supplementa-
tion or treatment resulted in 32.52 mg/day reduction in 
serum concentrations of triglycerides through six studies 
(WMD: − 32.52; 95% CI: − 57.57, − 7.47) (Fig.  3a). To 
find an explanation for the between-study heterogeneity, 
we performed subgroup analyses by the participants’ age 
(< 50 years vs. ≥ 50 years), administration method (sin-
gle vs. double dose/continuous), and the duration of study 
(< 12 weeks v. ≥ 12 weeks) (Table 2); none of these sub-
group analyses changed our overall findings. In addition, 
we repeated our analysis after excluding one study that was 
conducted on hemodialysis patients, and findings remained 
unchanged (WMD: − 43.41; 95% CI: − 71.68, − 15.15) 
(data not shown). Combining findings from five studies 
showed a significant reduction in cholesterol concentrations 
NOTE: Weights are from random effects analysis
Overall  (I-squared = 0.0%, p = 0.612)
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following the administration of vitamin D (WMD: − 7.93; 
95% CI: − 13.03, − 2.83) (Fig. 3b). These findings remained 
unchanged after excluding a study that was done on HD 
patients (WMD: − 9.41; 95% CI: − 15.71, − 3.11) (data not 
shown). However, no significant effect of vitamin D supple-
mentation or treatment was seen on LDL (WMD: − 22.66; 
95% CI: − 47.58, 2.25) and HDL cholesterol levels (WMD: 
0.93; 95% CI: − 0.85, 2.72), through four included studies 
(Fig. 3c, d).
Findings for the effect of vitamin D on CRP levels
Pooling findings from 11 studies showed no signifi-
cant effect of vitamin D supplementation or treatment 
on CRP concentrations (WMD: − 0.54; 95% CI: − 1.79, 
0.71) (Fig. 3e). Due to a high between-study heterogene-
ity (I2 = 88.2%), we performed subgroup analyses based 
on participants’ age (< 50  years vs. ≥ 50  years), study 
design (RCT vs. open-label CT), administration method 
(daily vs. single or double dose/continuous), study dura-
tion (< 6 months vs. ≥ 6 months), control type (placebo 
vs. non-placebo), and disease stage (HD vs. non-HD) 
(Table 2). Vitamin D supplementation or treatment resulted 
in a significant reduction in circulating CRP among stud-
ies with participants ≥ 50  years of age (WMD: − 1.64; 
95% CI: − 2.42, − 0.86), RCTs (WMD: − 0.48; 95% 
CI: − 0.87, − 0.09), when vitamin D was administered con-
tinuously (WMD: − 0.44; 95% CI: − 0.81, − 0.07), with 
an intervention duration of < 6  months (WMD: − 0.68; 
95% CI: − 1.09, − 0.27), or used placebo among controls 
(WMD: − 0.48; 95% CI: − 0.87, − 0.09), and among patients 
with HD (WMD: − 0.51; 95% CI: − 0.93, − 0.10). The effect 
of vitamin D supplementation or treatment on CRP con-
centrations was not significant in all other subgroups. Fur-
thermore, meta-regression did not provide a significant 
dose–response association between dosage and serum levels 
of CRP (P = 0.42).
Sensitivity analysis and publication bias
We had sufficient data to explore sensitivity analysis and 
publication bias only for the effect of vitamin D supple-
mentation or treatment on CRP levels. Visual inspection 
of the funnel plot and Egger regression test (P = 0.88) 
Table 2  Subgroup analyses for the effects of vitamin D supplementation or treatment on metabolic profiles in patients with chronic kidney dis-
ease
CRP C-reactive protein, CT controlled trial, RCT randomized controlled trial
Variables Subgroups Number of 
effect sizes
Pooled WMD 95% CI I2 (%) Between-
study I2 
(%)
Fasting glucose Participants’ age < 50 years 2 − 16.68 − 19.16, − 14.19 71.3 0.10
≥ 50 years 3 − 19.80 − 22.13, − 17.48 76.8
Triglycerides Participants’ age < 50 years 2 − 12.03 − 20.15, − 3.92 87.3 < 0.001
≥ 50 years 4 − 37.04 − 46.38, − 27.69 91.0
Administration method Single or double doses 2 − 22.83 − 30.22, − 15.45 97.8 0.98
Continuous administration 4 − 22.68 − 33.66, − 11.70 80.1
Study duration < 12 weeks 2 − 22.30 − 43.53, − 1.07 90.0 0.96
≥ 12 weeks 4 − 22.83 − 29.23, − 16.43 94.2
CRP Participants’ age Adult 6 − 0.19 − 0.58, 0.21 91.4 0.001
Elderly 5 − 1.64 − 2.42, − 0.86 75.9
Country Eastern 4 − 0.45 − 1.16, 0.25 95.6 0.91
Western 7 − 0.50 − 0.91, − 0.09 63.6
Study design RCT 9 − 0.48 − 0.87, − 0.09 90.6 0.94
Open-label CT 2 − 0.51 − 1.36, 0.33 0.0
Administration method Daily doses 2 − 0.62 − 2.09, 0.85 0.0 0.24
Single or double doses 2 − 3.12 − 6.25, 0.01 0.0
Continuous administration 7 − 0.44 − 0.81, − 0.07 92.7
Study duration < 6 months 6 − 0.68 − 1.09, − 0.27 81.2 0.07
≥ 6 months 5 0.07 − 0.63, 0.76 92.7
Control group Placebo 9 − 0.48 − 0.87, − 0.09 90.6 0.94
Non-placebo 2 − 0.51 − 1.36, 0.33 0.0
Health condition Hemodialysis 6 − 0.51 − 0.93, − 0.10 93.7 0.80
Non-hemodialysis 5 − 0.41 − 1.10, 0.27 32.5
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provided no evidence for the presence of publication bias 
(Fig. 4). In addition, sensitivity analysis showed that no 
individual study had a great influence on the final results.
Discussion
To the extent of our knowledge, this is the first meta-anal-
ysis to assess the effect of vitamin D supplementation or 
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Fig. 3  Meta-analysis lipid profiles weighted mean difference estimates for a triglycerides, b total, c LDL, d HDL cholesterol, e CRP in the vita-
min D supplements and control groups (CI = 95%)
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treatment on glycemic control, lipid profiles and CRP lev-
els in CKD patients. Based on our results, vitamin D sup-
plementation or treatment significantly improved fasting 
glucose, HOMA-IR, triglycerides, and cholesterol levels 
among patients with CKD, though it did not influence insu-
lin, HbA1c, LDL and HDL cholesterol, and CRP levels.
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Effects of vitamin D supplementation or treatment 
on glycemic control
It was reported that 415 million adults (20 to 79 years old) 
had diabetes mellitus in 2015 [49]. Patients with diabetes 
have a greater risk of death and cardiovascular disease than 
the general population [37]. This meta-analysis showed that 
vitamin D had a therapeutic impact on glycemic control 
(fasting glucose and HOMA-IR) of CKD patients, but did 
not affect insulin and HbA1c levels. There are many studies 
examining the effect of vitamin D supplementation or treat-
ment on glycemic control, but results are conflicting. In a 
meta-analysis conducted by Mirhosseini et al. [29], vitamin 
D supplementation significantly decreased fasting glucose, 
HOMA-IR and HbA1c levels in individuals with pre-diabe-
tes. Moreover, vitamin D supplementation led to a signifi-
cant reduction in HOMA-IR in patients with T2DM, though 
no significant improvement in fasting glucose, HbA1C 
and insulin was observed. However, in subgroup analysis, 
vitamin D supplementation of > 2000 IU/day resulted in a 
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ing the publication bias for the 
effect of vitamin D on CRP
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significant reduction in fasting glucose [22]. Another review 
has evaluated the effects of vitamin D supplementation on 
glycemic control among patients with non-alcoholic fatty 
liver disease [39]. They observed that taking vitamin D sup-
plements had no significant effect on fasting glucose, insulin, 
HOMA-IR and HbA1c [39]. However, they included five tri-
als while a high dosage of vitamin D (50,000 IU/week) was 
administered only in one trial in which reduction in HOMA-
IR and fasting glucose was observed [13]. Also, Akbari et al. 
conducted a meta-analysis to examine the effects of vitamin 
D supplementation on gestational diabetes mellitus (GDM) 
patients and found a significant reduction in HOMA-IR, but 
vitamin D supplementation had no effect on fasting glu-
cose, insulin, and HbA1c [1]. Although the exact mecha-
nisms through which vitamin D supplementation or treat-
ment might influence glucose homeostasis, limited possible 
mechanisms are suggested. It has been observed that vitamin 
D can modify function of β-cells in the pancreas. In addi-
tion, vitamin D can affect insulin receptors and subsequently 
improve insulin sensitivity. Another proposed mechanism is 
mediated through suppressing inflammatory markers, which 
in turn improves insulin sensitivity [3].
Effects of vitamin D supplementation or treatment 
on lipid profiles
This meta-analysis showed that vitamin D supplementation 
or treatment in patients with CKD could decrease triglycer-
ides and total cholesterol levels, while it did not influence 
LDL and HDL cholesterol levels. Tabrizi et al. [39] observed 
that vitamin D supplementation had no significant effect on 
blood lipids in patients with non-alcoholic fatty liver disease. 
In another meta-analysis, vitamin D administration resulted 
in a significant rise in LDL cholesterol levels, but did not 
have any effect on triglycerides, total and HDL cholesterol 
levels [44]. Another meta-analysis showed that vitamin D 
supplements could reduce triglycerides, total and HDL cho-
lesterol, whereas it did not improve HDL cholesterol levels 
[18]. Supplementation with vitamin D in patients with GDM 
resulted in a significant reduction in serum LDL cholesterol 
concentrations, while it did not influence serum levels of tri-
glycerides, total and HDL cholesterol [1]. These differences 
in findings might be partially due to the fact that the effect 
of vitamin D supplementation or treatment on serum lipids 
might be influenced by some other factors including dosage, 
duration of intervention, and baseline levels of vitamin D, 
which can be also altered by geographical latitudes. There-
fore, bigger studies considering baseline levels of vitamin 
D are required to shed light on this issue. The probable role 
of vitamin D on lipid metabolism could be explained by the 
PPAR-α pathway. Vitamin D can increase the expression of 
PPAR-α, which has an essential role in lipid metabolism in 
hepatocytes [34]. In the current meta-analysis, insulin and 
HbA1c levels were not affected by vitamin D which was 
against our hypothesis. This may have few reasons. The 
study duration may be one possible explanation for such dis-
crepancy. Most included RCTs were conducted ≤ 12 weeks, 
which is far shorter than those observational studies. It is 
known that HbA1c represents an integrated measure of gly-
cemic control over a period of > 12 weeks. The use of such 
measurements in studies with a short duration of vitamin D 
administration may underestimate any effects of vitamin D 
on glycemic control. A longer duration of RCTs is required 
to obtain a more reliable conclusion. In addition, dosage 
of vitamin D may affect insulin and HbA1c levels. There-
fore, higher doses of vitamin D (4000 IU/day) appear to 
be required to achieve a significant increase in insulin and 
HbA1c levels. Also, pro-inflammatory markers in patients 
with T2DM may influence glucose levels and HOMA-IR, 
but this may not affect insulin and HbA1c levels.
Effects of vitamin D supplementation or treatment 
on CRP
We observed that vitamin D supplementation or treatment 
in patients with CKD did not affect CRP levels. It is a well-
known fact that vitamin D has anti-inflammatory properties 
[6, 42]. Mansournia et al. [26] conducted a meta-analysis 
consisting of 16 studies and found that vitamin D interven-
tion significantly decreased CRP levels in patients with dia-
betes. In another meta-analysis, vitamin D supplementation 
in patients with diabetes resulted in a 0.45 μg/mL reduction 
in serum CRP concentrations [47]. In another meta-analysis, 
Akbari et al. [2] showed a significant reduction in serum 
concentrations of CRP following supplementation with vita-
min D. One pathway through which vitamin D can affect 
CRP concentrations is the inhibition of inflammatory mark-
ers synthesis as well as inhibition of inflammatory markers 
production by influencing on the immune cells like T helper, 
lymphocytes, and monocytes. One of these inflammatory 
markers is interleukin-6, which stimulates CRP production 
in the liver [23]. There is growing evidence that vitamin D 
exerts regulatory influence on immune system cells [33]. It 
has been shown that serum levels of cholecalciferol are piv-
otal for the optimum anti-inflammatory response of mono-
cytes in humans [48]. The conversion of cholecalciferol to 
its active form, calcitriol, occurs locally in cells of immune 
system [5]. Calcitriol has an anti-inflammatory impact on 
the inflammatory profile of monocytes, decreasing produc-
tion of various pro-inflammatory markers such as TNF-α, 
IL-1β, IL-6, and IL-8 [14]. Furthermore, immediate anti-
inflammatory impact of vitamin D occurs in cells that have 
the vitamin D receptor (VDR) [43]. Interaction of cholecal-
ciferol and VDR leads to anti-inflammatory influences via 
inhibition of NF-κB and STAT1/5 signaling pathways. This 
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causes reduced transcription of pro-inflammatory cytokines 
[5].
In conclusion, this meta-analysis demonstrated the ben-
eficial effects of vitamin D supplementation or treatment 
on improving fasting glucose, HOMA-IR, triglycerides and 
cholesterol levels among patients with CKD, though it did 
not influence insulin, HbA1c, LDL and HDL cholesterol, 
and CRP levels. These findings indicated that vitamin D 
supplementation or treatment might have some other benefi-
cial effects for metabolic control in patients with CKD, who 
are mostly suffering from diabetes, rather than bone health 
protection. Due to the heterogeneity between studies, as a 
result of variations in the dosage, frequency, or duration of 
vitamin D supplementation or treatment, the results of this 
meta-analysis should be interpreted with caution.
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